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Abstract
The feasibility of making calcium carbonate-calcium phosphate (CaCO3-CaP) mixed cements,
comprising at least 40 % (w/w) CaCO3 in the dry powder ingredients, has been demonstrated.
Several original cement compositions were obtained by mixing metastable crystalline calcium
carbonate phases with metastable amorphous or  crystalline calcium phosphate powders in
aqueous medium. The cements set within at most 1 hour at 37°C in atmosphere saturated with
water. The hardened cement is microporous and exhibits weak compressive strength. The
setting reaction appeared to be essentially related to the formation of a highly carbonated
nanocrystalline apatite phase by reaction of the mestastable CaP phase with part or almost all
of the metastable CaCO3 phase. The recrystallization of metastable CaP varieties led to a final
cement consisting of a highly carbonated poorly crystalline apatite (PCA) analogous to bone
mineral  associated  with  various  amounts  of  vaterite  and/or  aragonite.  The  presence  of
controlled amounts of CaCO3 with a higher solubility than the apatite formed in the well-
developed calcium phosphate cements might  be  of  interest  to  increase  resorption  rates  in
biomedical cement and favor its replacement by bone tissue. Cytotoxicity testing revealed
excellent cytocompatibility of CaCO3-CaP mixed cement compositions.
Keywords:  bone  cement,  calcium  carbonate,  calcium  phosphate,  FTIR  spectroscopy,
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Introduction
Among the large variety of biomaterials now available,  an  increasing  number  of  calcium
phosphate  (CaP)  ceramics  and  cements  are  used  as  bone  substitutes  in  orthopaedic  and
maxillo-facial surgery [1]. Fast-setting CaP bone cements have been studied in depth and
developed in the last few years essentially as bone filling and bone reinforcement biomaterials
due  to  their  excellent  biocompatibility  and  bioactivity.  However,  even  though  they  can
perfectly fill a bone cavity and be shaped as desired [2-10], one of the main concerns of
surgeons is to reach higher rates of resorption, an improvement of bone reconstruction and to
a lesser extent higher mechanical resistance [11-13].
Several types of setting reaction can be involved in CaP biomimetic cements hardening and
many of them lead to the formation of poorly crystalline apatites with a varying degree of
crystallization  and  carbonation.  The  aim  of  biomimetic  bone  cements  is  to  disturb  bone
functions and properties as little as possible and to behave similarly to bone tissue. From a
biological point of vue, this term defines cements which can reproduce the composition, the
structure, the morphology and the crystallinity of bone crystals [14].
Bone  mineral  is  described  as  a  poorly  crystalline  non-stoichiometric  apatite  and  several
studies  have  revealed  the  existence  of  non-apatitic,  labile  environments  of  mineral  ions
probably located at the surface of the crystals [15-16]. These specific ion environments have
been shown to be directly related to the reactivity of poorly crystalline apatites (PCA) and
bone mineral [16-17]. The solubility of apatites depends on the presence of vacancies and the
molar Ca/(P+C) ratio (P for phosphate ions and C for carbonate ions) [18]. Carbonate ions can
be  incorporated  into  the  apatite  stucture  and  substitute  for  anions  (phosphates  and/or
hydroxide ions) [19]. The lower this ratio, the higher the amount of lacunae and the less the
cohesiveness of the crystals which implies higher solubility. Other physical chemical factors
such as porosity or the presence of labile non-apatitic environments have been found to affect
cement biodegradation properties.
The resorption properties of mineral biomaterials are generally believed to be related to the
solubility of their constitutive CaP phases. Several ceramic and cement compositions have
been studied to improve the bioactivity and biodegradation properties [14, 20]. For example,
the concept of biphasic calcium phosphate (BCP) ceramics is based on the optimum balance
between more stable (hydroxyapatite,  HA)  and  more  soluble  (tricalcium  phosphate,  TCP)
phases to control material resorption [21]. This is based on the dissolution/transformation
processes of TCP and HA which depend on several factors such as the composition of theNew CaCO3-CaP mixed cement compositions
phases and the sintering temperature  and  conditions.  Another  example  is  coralline  HA,  a
carbonated  hydroxyapatite  which  is  prepared  by  the  hydrothermal  conversion  of  calcium
carbonate from coral in the presence of ammonium phosphate [22-23]. It has been suggested
that controlling the thickness of hydroxyapatite on a CaCO3 matrix could control the rate of
resorption of the implant and its replacement by newly formed bone [24]. The concept of
biphasic ceramics has however sparsely been developed in view of controlling the resorption
of ionic cements [25-29]. Calcium carbonate compounds have a higher solubility than apatite
[30-31] and although some mineral cements containing calcium carbonate have already been
proposed, the use of very large proportions of calcium carbonate (³ 20% w/w in the dry
powder ingredients) opens new possibilities which have not yet been explored [4, 26, 32-33].
Several varieties of calcium carbonate (in increasing order of solubility of the CaCO3 phase:
calcite (C), aragonite (Ar), vaterite (V) and amorphous calcium carbonate (ACC)) can be
encountered in nature [34]. Calcium carbonates of biological origin (nacre and coral) and their
derivatives have been used as biocompatible and bioactive bone substitutes in the form of
powder, porous ceramic or associated with organic gels for more than 20 years [35-39].
Very  recently,  Combes  et  al.  demonstrated  the  feasibility  of  calcium  carbonate-based
biomedical cements consisting of 100% CaCO3 [40-42]. In order to propose a wide range of
cement compositions, we present here a CaCO3-CaP mixed cement concept which is based on
the idea that biphasic cements could be prepared which could behave in the same way as
biphasic ceramics. Calcium carbonate and biomimetic apatites appear to be one of the most
interesting associations for bone filling and repair as biodegradation could be controlled by
the proportion of the more soluble CaCO3 in the final cement composition. The CaCO3-CaP
mixed cement concept is based on the reactivity of biphasic or triphasic mixtures of highly
reactive  calcium carbonate  and  calcium  phosphate  powders  comprising  amorphous  and/or
metastable crystalline phases in the presence of small amounts of aqueous medium. Such
cements can be simply obtained by mixing calcium carbonate and calcium phosphate phases
in  aqueous  media.  Moreover,  cements,  unlike  materials  obtained  by  high  temperature
sintering or natural materials, can be intimately associated with biologically active molecules
(specific proteins, antibiotics, etc.) to improve bone reconstruction [43-44].
In this paper we present our preliminary investigations on this new type of bone cement:
CaCO3-CaP  mixed  cements.  FTIR  spectroscopy  and  X-ray  diffraction  were  performed  to
understand the reactions responsible for the setting and hardening of these cements. Setting
kinetics  and  mechanical  properties  were  also  investigated.  Cytoxicity  tests,  a  prerequisite
before in vivo evaluation, were also performed.New CaCO3-CaP mixed cement compositions
Materials and Methods
Preparation and characterisation of powders
Calcium  carbonate  crystalline  phases  (aragonite  (Ar)  and  vaterite  (V))  were  prepared  by
double decomposition between a calcium chloride solution (7.35 g in 500 ml of deionized
water for Ar; 36.75 g in 250 ml of deionized water for V) and a sodium carbonate solution
(5.30 g + 0.08 g strontium chloride in 500 ml of deionized water for Ar; 26.50 g in 250 ml of
deionized water for V) at 100°C for aragonite and at 30°C for vaterite. Then the precipitates
were filtered and washed with 1 litre of deionized water.
Crystalline and amorphous calcium phosphate phases were prepared by double decomposition
between  a  calcium  nitrate  solution  (86.74  g  in  600  ml  of  deionized  water  for  dicalcium
phosphate dihydrate (DCPD or brushite; CaHPO4. 2H2O); 47 g in 500 ml of deionized water
+  20  ml  of  ammonium  hydroxide  solution  at  20  %  for  amorphous  tricalcium  phosphate
(TCPam; Ca3(PO4)2. nH2O)) and an ammonium dihydrogenphosphate solution (42.26 g in
1400 ml of deionized water + 20 ml of ammonium hydroxide solution at 20 %) for DCPD
synthesis and a di-ammonium hydrogenphosphate solution (26 g in 1300 ml of deionized
water + 20 ml of ammonium hydroxide solution at 20 %) for TCPam. Then the precipitates
were rapidly filtered and washed (with 2 litres of deionized water for DCPD and 7 litres of
deionized  water  +  35  ml  of  ammonium  hydroxide  solution  at  20  %  for  TCPam).  Heat
treatment of the amorphous tricalcium phosphate at 400°C during 30 minutes was then carried
out to eliminate water associated with crystals while keeping amorphous structure.
After filtration and washing, the precipitates were lyophilised and the powders stored in a
freezer.
All the synthesised powders were characterised by transmission FTIR spectroscopy from KBr
pellets  (Perkin  Elmer  FTIR  1600  spectrometer)  and  X-ray  diffraction  (Inel  CPS  120
diffractometer) using a Co anticathode.
Preparation and characterisation of the cements
The cement powders were made up of a mixture of metastable calcium carbonate and calcium
phosphate phases; CaCO3 made up at least 40 % (w/w) of the cement dry powder ingredients.
The cement paste was obtained by mixing the powders, which had been first homogenised in
a  mortar,  with  an  appropriate  amount  of  liquid  phase  (either  deionized  water  or  sodium
chloride  solution  (0.9  %  w/w)).  The  amount  of  solution  was  determined  to  allow  the
formation of a mouldable paste. We chose to test the use of isotonic solution (0.9 % (w/w)New CaCO3-CaP mixed cement compositions
NaCl  solution)  as  it  is  already  the  liquid  phase  of  some  cements  (like  alpha-BSM
®)  and
because it could open the possibility to use blood serum as liquid phase.
The wet paste was placed in a sealed container saturated with H2O at 37°C for setting and
hardening. In vitro cement evolution in an atmosphere saturated with water can be compared
to in vivo cement evolution in contact with biological tissues.
The carbonate content of cements was checked using a CO2 coulometer (Coulometrics Inc.,
USA) that measures the CO2 released during sample dissolution in acidic conditions (HClO4,
2M) and in a closed system. The CO2 released is transferred into a photometric cell in a non-
aqueous medium and titrated through an acid-base reaction [45].
To further characterize the carbonated apatite formed after cement setting and hardening, we
decomposed the n2CO3 domain according to the work of Bohic and co-workers [46]. Three
bands can be detected by FTIR spectroscopy at 867, 872 and 879 cm
-1 which have been
respectively assigned to type A carbonated apatite (carbonate ions substituted for OH ions in
the  hydroxyapatite  structure),  type  B  carbonated  apatite  (carbonate  ions  substituted  for
phosphate groups in the hydroxyapatite structure) and non-apatitic carbonate ions probably
located at the surface of the crystals. In addition, the n2CO3 bands may be superimposed on a
broad  band  due  to  HPO4
2-  ions  which  might  be  present  in  such  PCA  analogous  to  bone
mineral. This band has been shown to interfere on the low wavenumber side of the n2CO3
domain [47]. However, the broadness of this band does not cause significant interference with
the CO3
2- band. The evaluation of carbonate type A/type B and non-apatitic/type B ratios
(noted  A/B  and  non-Ap/B  ratios,  respectively)  by  FTIR  spectroscopy  was  performed  by
curve-fitting  in  the  n2CO3  domain  (900-800  cm
-1)  using  Grams/32  software  (Galactic
Industries Corporation). In this domain, the CaCO3 crystal types (calcite, aragonite, vaterite)
showed  a  sharp  and  intense  absorption  band  at  855  cm
-1  for  aragonite  and  875  cm
-1  for
vaterite and calcite.
Observation of cements by scanning electron microscopy (SEM) was carried out using a Leo
435 VP microscope. Small pieces of hardened and dried cement samples were placed and
fixed on a support with double faced carbon tape.
Setting time and compressive strength measurementsNew CaCO3-CaP mixed cement compositions
The setting rate of the cement was followed with a TA–XT2 Texture Analyser fitted with a
cylindrical needle (0.7 mm in diameter). The setting time was considered to be reached when
the paste developed a resistance to needle penetration greater than 600 g/mm
2.
The compressive strength of the cement was evaluated using a Hounsfield Series S apparatus.
The cement paste was placed in a cylindrical mould (height / diameter ratio @ 2 and diameter
equal to 10.5 mm) and packed tightly in order to eliminate air bubbles trapped in the paste.
The paste was left to set and harden at 37°C in a sealed container saturated with water for 1
day. The hardened cement was withdrawn from the container and left to dry for 1 week at
37°C. The cement was then removed from the mould and the compressive test performed.
Indirect cytotoxicity evaluation
The indirect cytotoxicity was assessed by an extraction method according to NFEN30993-5
ISO 10993-5 [48-49]. Osteoprogenitor cells arising from human bone marrow according to
Vilamitjana-Amédée et al. with some modifications [50] were used for testing the extracts
and  cultured  in  Iscove  Modified  Dulbecco's  Medium  (IMDM,  Sigma  Aldrich,  France)
containing 10% foetal calf serum (FSC, Sigma, France).
The cells were seeded at a density of 40 000 cells/cm
2 in 96-well microtiter plates (Nunc,
Denmark)  and  the  culture  was  maintained  at  37°C  for  96  h  after  cell  plating.  At
subconfluency  the  medium  was  replaced  by  the  cement  extraction  vehicle.  To  obtain
extraction vehicles, fragments of sterile hardened cement were immersed in IMDM. The ratio
of the sample  surface  area  to  the  volume  of  the  vehicle  was  5  cm
2/ml.  Extractions  were
performed in borosilicate  glass tubes at 37°C  for  120  h  without  stirring  according  to  the
standard procedures. Borosilicate tubes containing identical extraction vehicles with either no
cement or a solution of phenol at a concentration of 6.4 g/l (known to be cytotoxic) were
processed under the same conditions to provide negative and positive controls, respectively.
The medium was removed and replaced by control extracts at various concentrations (100%
(v/v), 50% (v/v), 10% (v/v), 1% (v/v)) in the culture medium for 24 h at 37°C. At the end of
the extract incubation period, tests were performed: cell viability (Neutral Red assay) and cell
metabolic activity (MTT assay) [51-52]. The intensity of the colors obtained (red and blue
respectively)  is  directly  proportional  to  the  viability  and  metabolic  activity  of  the  cell
population and inversely proportional to the toxicity of the material. Indirect cytotoxicity tests
were duplicated for each cement composition. The mean values of absorbance measurements
obtained  from  colorimetric  tests  and  their  corresponding  standard  deviation  (±  SD)  wereNew CaCO3-CaP mixed cement compositions
calculated. The results were expressed as a percentage of the negative control (plastic) tested
during the same experiment.
Results
Three examples of initial powder mixtures that lead to hardened cements are reported in table
1. The liquid-to-solid ratio (L/S) ranges between 0.5 and 0.72 depending on the composition
of the powder mixture. For a given powder mixture composition, this ratio can vary to some
extent but the value reported corresponds to the optimum final mechanical resistance of the
cement.
The  setting  time  and  the  compressive  strength  of  (Ar+V+Br),  (V+Br)  and  (V+TCPam)
cements are reported in table 1. Just after mixing the powders with the liquid phase, the paste
was viscous and easily mouldable for several minutes. The cements set within one hour and
hardened. Slower setting (i.e. longer setting times) and higher compressive resistance were
measured  for  cements  prepared  with  vaterite  and  brushite  mixtures.  In  all  cases,  the
compressive strength remained rather weak (£ 13 MPa).
Figure 1 shows the X-ray diffraction (XRD) diagrams of two examples of CaCO3-CaP mixed
cements  after  setting  and  hardening.  The  final  composition  of  such  cements  comprises  a
poorly crystalline apatite analogous to bone mineral which can be associated with a calcium
carbonate crystalline phase (vaterite, aragonite or calcite) depending on the relative amount of
phosphate compound in the initial mixture. For example, vaterite was present in the final
composition of (V+Br) cement (see figure 1) and  also of (V+TCPam) cement. The XRD
diagram of the (V+TCPam) cement (not presented) was  similar to that of (V+Br) cement. A
small amount of brushite was seen to remain in the hardened (V+Br) cement. For (Ar+V+Br)
cement,  no  crystalline  CaCO3  phase  was  detected  by  X-ray  diffraction  analysis  and  the
corresponding X-ray diagram is quite analogous to that of bone (see figure 1).
The  FTIR  spectra  of  different  mixed  CaCO3-CaP  cements  analyzed  after  setting  and
hardening at 37°C are presented in figure 2. The analogy of (Ar+V+Br) cement with bone
mineral  is  confirmed  by  FTIR  spectroscopy.  However,  we  can  clearly  notice  the  higher
intensity of the absorption bands in the n2CO3 and n3CO3 domains revealing the presence of a
highly carbonated apatite and/or calcium carbonate compounds. The decomposition of the
n2CO3 domain of (Ar+V+Br) cement spectrum into 6 subbands (see figure 3) revealed the
formation of an AB type carbonated apatite analogous to bone mineral. The calculated area
ratios based on FTIR data were 0.40 and 0.88 for A/B and non-Ap/B ratios respectively.
These different values indicate that B type carbonate is the main species and that a largeNew CaCO3-CaP mixed cement compositions
proportion of CO3
2- (non-apatitic CO3
2-) is located at the surface of apatite crystals. The broad
band, assigned to HPO4
2- ions, appeared clearly on the low wavenumber side of the n2CO3
domain.
In addition, the decomposition of the n2CO3 domain of (Ar+V+Br) cement reveals a peak at
855  cm
-1  assigned  to  carbonate  groups  in  aragonite.  The  presence  of  a  small  amount  of
aragonite  associated  with  PCA  was  confirmed  by  the  presence  of  the  two  characteristic
absorption bands of aragonite at 700 and 713 cm
-1 in the n4CO3 domain (figure 2). These
results showed that the detection limit of FTIR spectroscopy for aragonite is higher than that
of X-ray diffraction.
For (V+Br)  cement, the  characteristic  bands  of  vaterite  at  875  cm
-1  and  745  cm
-1  can  be
distinguished in the n2CO3 and n4CO3 domains respectively which confirmed the presence of
untransformed vaterite in the hardened cement also detected by X-ray diffraction analysis.
For the two kinds of cement, we observed a decrease of the FTIR band width of all CO3 and
PO4 vibration bands compared to those of bone mineral suggesting a better crystallinity of
PCA in cement than in bone. The X-ray diffraction peaks for bone also appeared broader than
those of the cements (see figure 1).
The total carbonate content in the initial powder mixture and the hardened cement for three
examples of CaCO3-CaP mixed cements are reported in table 2. It varies from 10 % to 21 %
for (Ar+V+Br) cement and (V+TCPam) cement respectively. In all cases, the strong decrease
of CO3
2- content for hardened cements compared to powder mixtures indicates that there is
release  of  CO2  during  the  setting  reaction.  The  formation  of  a  highly  carbonated  apatite
analogous to bone mineral was confirmed for (Ar+V+Br) cement; the weight proportion of
CO3
2- was 10 %. This value is in the range of carbonate contents found for human bone.
Figure 4 shows SEM micrographs of (V+TCPam) and (V+Br) cement. The hardened cements
appeared to be mainly formed of a poorly crystalline phase. For (V+Br) cement, the platelet
crystals of brushite disappeared after setting and hardening.
Many spherical micropores can be seen in (V+TCPam) cement (see figures 4c and 4d). These
micropores do not however seem to be interconnected.
The results of the indirect biocompatibility study following incubation of cells with cement
extracts at different dilutions, presented in figure 5, showed no cytotoxicity effect of cements
prepared with (Ar+V+Br) and (V+Br) mixtures. Values of cell viability obtained for undiluted
extracts were (102 ± 10 ) % for (Ar+V+Br) and (114 ± 14) % for (V+Br) which are close to
the  100%  value  for  the  referenced  control  (plastic).  The  results  of  metabolic  activityNew CaCO3-CaP mixed cement compositions
measurement for undiluted extract were also close to the 100  % value  for the referenced
control (plastic) ((94 ± 6 ) % for (Ar+V+Br) and (100 ± 13) % for (V+Br)). No significant
difference was ever noted for the two cement compositions or between the different extract
dilutions (1 to 100 %).
Discussion
CaCO3-CaP mixed cement compositions
The  calcium  carbonate-calcium  phosphate  (CaCO3-CaP)  mixed  cements  presented  in  this
paper and the trial compositions, especially (V+Br; 1:1) and (V+TCPam; 1:1), are the first
CaCO3-CaP  mixed  cements  for  biomedical  applications  with  more  than  20  %  calcium
carbonate(s) in the initial powder mixtures. Several CaP biomedical cement formulations that
incorporate a certain proportion of CaCO3 have been designed to improve the mechanical
properties of the cement or its compliance or to create macroporosity but the proportion of
calcium  carbonate  in  such  cement  compositions  did  not  exceed  15%  (w/w)  and  the  final
product did not contain a calcium carbonate phase [4, 26, 32-33]. However, we can note that
very  recently  Combes  and  co-workers  demonstrated  the  feasibility  of  calcium  carbonate
biomedical cements composed of 100 % CaCO3 [41].
The CaCO3-CaP mixed cement compositions proposed here can be prepared straightforwardly
by  simply  mixing  water  (liquid  phase)  with  calcium  carbonate  phase(s)  and  a  calcium
phosphate  phase  (solid  phase)  which  can  be  easily  obtained  by  precipitation.  The  initial
composition of CaCO3-CaP mixed cements comprised a powder biphasic or ternary mixture
including metastable calcium carbonate crystalline phase(s) (³ 40 % w/w in the dry powder
ingredients) and a crystalline or amorphous calcium phosphate phase.
Among all the powder combinations tested, three dry powder compositions including at least
42  %  of  calcium  carbonate  phase(s)  appeared  as  promising  formulations  for  CaCO3-CaP
mixed  cements.  However,  the  initial  cement  compositions  are  not  limited  to  the  three
presented in table 1 and other (CaCO3+CaP) powder mixtures ((Ar+Br; 1:2; L/S = 0.5) and
(V+Ar+TCPam; 1:1:3;  L/S = 0.8) mixtures for example) were in fact tested  but  led  to  a
setting  paste  with  poor  compressive  strength.  However,  not  all  the  parameters  of  these
complex  mixtures  have  been  optimised  and  mechanical  resistance  could  certainly  be
improved with further investigations on these cement compositions.
In a preliminary study of CaCO3-CaP mixed cement compositions, especially initial mixtures
of aragonite and brushite (1:2 (w:w)) for example), FTIR and XRD analyses revealed that theNew CaCO3-CaP mixed cement compositions
resulting cement was made up of brushite, aragonite and a small quantity of poorly crystalline
apatite, the formation of which appeared to determine cement setting. This was an original
and interesting final composition that can be compared to the brushite-type calcium phosphate
cement setting reaction which produces DCPD [3]. The final composition of (Ar+Br) cement
associating mostly DCPD and aragonite which have a higher solubility than PCA, probably
infers  a  high  biodegradation  rate  along  with  less  acid  release  than  for  brushite  calcium
phosphate cements. Indeed, aragonite (basic component) would partly moderate the drop of
pH  accompanying  the  transformation  of  DCPD  into  PCA.  However,  as  the  setting  and
hardening  time  of  (Ar+Br)  cement  can  be  longer  than  12  h,  we  decided  to  discard  this
composition from future investigations.
FTIR spectroscopy and X-ray diffraction analyses showed that for the cement compositions
presented  herein  a  poorly  crystalline  apatite  (PCA)  analogous  to  bone  mineral  (AB  type
carbonated  apatite)  associated  or  not  with  untransformed  crystalline  CaP  and/or  CaCO3
phases is involved in the final cement compositions. In addition, the preparation of CaCO3-
CaP mixed cements either with water or NaCl solution (0.9 % w/w) did not significantly
modify the composition, the setting or hardening reactions.
AB type carbonated apatites analogous to bone mineral can be described by the following
general chemical formula [16]:
Ca10-x (PO4)6-x(HPO4 and CO3)x (OH and ½ CO3)2-x
For (Ar+V+Br) cement, the high value of the non-Ap/B ratio determined from FTIR data
indicated that a large proportion of carbonate ions in the PCA were in the hydrated layer (non-
apatitic CO3
2- ions) [16, 18]. This observation is interesting as carbonate species slow down
the maturation of apatite nanocrystals and stabilise them in their native very reactive form.
In addition, the presence of non-apatitic HPO4
2- and PO4
3- groups, located in the hydrated
PCA surface layer, can be revealed by decomposition of the n4 PO4 band of the cement FTIR
spectrum [16, 18].
An interesting ability of these CaCO3-CaP mixed cement compositions is to reach very high
carbonate contents and even to produce in most cases biphasic systems (CaCO3 and CaP
compounds)  offering  a  wide  range  of  CaCO3-CaP  mixed  final  compositions.  Indeed,  by
comparing (V+Ar+Br) and (V+Br) cement final composition (see figure 1), we can clearly see
that the proportion of calcium carbonate associated with PCA varied significantly and we can
consider  preparing  and  adapting  the  cement  composition  and  thus  its  biodegradationNew CaCO3-CaP mixed cement compositions
properties  depending  on  the  biomedical  applications.  However,  from  these  preliminary
investigations it appears difficult to precisely anticipate the final cement composition due to
the  CO2  release  that  occurs  during  the  setting  and  hardening  reactions  (see  equation  1
hereafter). The composition of the apatite formed cannot be precisely determined due to the
presence of CaCO3 phase(s) remaining in the hardened cement and to the lack of analytical
methods to evaluate the proportion of CaCO3 in these biphasic cements. Part of our future
investigations into such cement compositions will focus on setting-up a quantitative method
based on FTIR spectroscopy and/or X-ray diffraction analysis to characterize the hardened
cement composition and thus indirectly quantify the CO2 released during cement preparation.
The possibility of having a large amount of calcium carbonate associated with PCA in the
hardened cement is an interesting feature. Indeed, due to the higher solubility  of  calcium
carbonate compared to apatite, we can expect a faster biodegradation rate for CaCO3-CaP
mixed cements than for CaP cements. The association of CaCO3 and PCA in the cement final
composition can be compared to the well-developed biphasic calcium phosphate ceramics
associating CaP phases with different solubilities (hydroxyapatite and tricalcium phosphate
for  example)  for  a  better  control  of  bioceramic  biodegradation  and  bone  reconstruction
processes [21].
As the CaCO3-CaP mixed cement concept presented in this paper involved the formation of
an apatitic phase analogous to bone mineral after setting, we can consider such compositions
as biomimetic like most of the well-known and studied CaP cements [14].
Setting and hardening reaction
In the case of CaCO3-CaP mixed bone cements, the type of reaction responsible for setting
and hardening differs from that of CaP-based cements in several aspects. CaP biomedical
cements  can  be  classified  into  two  main  categories:  apatite  and  brushite  cements  that
respectively  lead  to  hydroxyapatite  and  brushite  (dicalcium  phosphate  dihydrate:  DCPD)
which could be converted into apatite in vivo [1, 53-54]. Two main types of setting reactions
can be distinguished for CaP cements: acid-base reaction and/or phase transformation (fast
hydrolysis for example) of a metastable CaP phase into apatite associated with respectively
more or less pH variation of the paste during setting. The involvement of acid-base and/or
phase  transformation  reactions  in  CaCO3-CaP  mixed  bone  cements  will  be  discussed
hereafter.New CaCO3-CaP mixed cement compositions
We have shown that the total content of CO3
2- in the hardened cement was, in all cases, lower
than the initial CO3
2- level in the powder mixture.
In the case of the CaCO3-brushite mixed cements presented herein ((V+Br) and (Ar+V+Br)
cements for example), the setting reaction appeared to be essentially related to the formation
of  a  highly  carbonated  nanocrystalline  apatite  analogous  to  bone  mineral  by  reaction  of
DCPD onto part or almost all of the CaCO3 metastable crystalline phase(s). Indeed, for all
cement compositions tested, no setting occurs if PCA is not formed. The decrease of the
CO3
2- level is related to the reaction of brushite hydrogenophosphate ions on carbonate ions of
vaterite or aragonite according to the following chemical reaction:
2 HPO4
2- + CO3
2-® 2 PO4
3- + CO2 + H2O Eq. (1)
As vaterite is a slightly basic component and brushite an acidic one, this setting reaction can
be related to a rather slow acid-base setting reaction of CaP cements. The release of CO2
induces microporosity (see figure 4) in the hard cement without visible swelling. In addition,
the water molecules from the DCPD transformation and the above reaction fill up the pores
between crystals and participate in the formation of a hydrated layer on the PCA nanocrystals.
SEM observations (figures 4a and 4b) support the fact that DCPD was transformed into PCA
by a dissolution-reprecipitation process as platelet crystals of DCPD are no longer visible in
the hardened cement and the remaining phase appeared poorly crystallized. However, a few
lentil-like crystals of vaterite can be distinguished on the surface (see figure 4b).
In the case of (V+TCPam) cement, upon contact with an aqueous solution, fast hydrolysis of
the amorphous tricalcium phosphate into a poorly crystalline apatite phase is involved in the
cement setting reaction. A reaction between phosphate and carbonate ions (equation 1) can
also occur and participate in the formation of a poorly crystalline carbonated apatite.  This
cement composition can be related to the a-BSM
Ò cement concept (ETEX Corp.) for which
the setting reaction also involves the fast hydrolysis of the amorphous CaP phase into apatite
[53]. The crystalline metastable CaP phase (DCPD) in the a-BSM
Ò cement composition acts
as  a  template  to  facilitate  apatite  crystal  nucleation  and  growth.  By  analogy  with  a-
BSM
Òcement, which is made up of a mixture of DCPD and TCPam, a preliminary study on
(V+TCPam) cement showed that the presence of metastable crystalline phases such as vaterite
appears essential for cement setting and hardening since upon admixture with water, pure
TCPam powder alone did not harden whereas the paste formed by a mixture of TCPam and
vaterite set and hardened. However, we have shown that a large amount of untransformedNew CaCO3-CaP mixed cement compositions
vaterite  can  be  detected  by  FTIR  spectroscopy  and  X-ray  diffraction  techniques  in  the
hardened cement suggesting that, in CaCO3-CaP mixed cements, the initial vaterite crystals
serve  as  a  template  for  the  crystallization  of  a  more  stable  calcium  phosphate  phase.
Furthermore, the stabilisation of vaterite and other calcium carbonate crystalline phases in the
presence  of  phosphate  ions  has  been  reported  by  several  authors  [55-56].  Thus,  the
dissolution-reprecipitation process of vaterite can be (partly) inhibited due to the adsorption of
phosphate ions onto the CaCO3 crystal surface.
In  the  case  of  (V+TCPam)  cement,  the  formation  of  OH
-  and  HPO4
2-  ions  during  the
formation  of  the  poorly  crystalline  apatite  from  TCPam  hydrolysis  can  be  related  to  the
hydrolysis of PO4
3- ions according to equation 2 [57]:
PO4
3- + H2O ® OH
- + HPO4
2- Eq. (2)
This chemical reaction is endothermic which could explain the necessity to warm the paste, to
37°C for example, for faster setting.
For the (V+TCPam) cement, the slight acidification of the paste during the hydrolysis of
TCPam along with the presence of carbonate ions from the calcium carbonate source could
explain the release of part of the carbonate. In addition, a fraction of carbonate ions can also
be incorporated in the apatite lattice.
We can assume that the reactions involved during CaCO3-CaP mixed cement formation do
not cause a significant pH variation of the paste due to  the presence of large amounts of
CaCO3 (basic component) that can moderate the pH drop during PCA formation. Moreover,
no visible change in pH (solution color) was observed when fragments of hardened cement
were immersed and equilibrated in the IMDM solution used for the indirect cytotoxicity test
which means that the products of the setting reaction and/or the residues are, as expected, not
highly acidic and/or basic compounds. In addition, no significant rise in paste temperature
was detected during paste preparation, setting or hardening.
Even if the result of the setting reaction might be different in vivo and in vitro especially due
to  the  reactivity  of  the  phases  in  the  hardened  cement,  one  of  the  remaining  questions
concerned the future of these constituting phases once implanted in vivo. The evolution of
DCPD and PCA in vivo is quite well documented as these CaP phases are involved in the
well-developed CaP bioceramics and cements whereas no precise data have been reported for
the in vivo physical-chemical  evolution  of  metastable  calcium  carbonate  phase(s)  such  asNew CaCO3-CaP mixed cement compositions
vaterite or aragonite. Unlike for calcium phosphates, only a few studies reported the level of
saturation of biological fluids with respect to calcium carbonate crystalline phase [58-59].
However, the work of Maeda et al. showed the high apatite-forming ability of titania-vaterite
composite in simulated body fluid solution due to the high solubility of vaterite suggesting
that vaterite is unstable in biological fluids [60]. Thus, we can consider that metastable CaCO3
(vaterite) in hardened cement will dissolve or be transformed rather rapidly after implantation.
Properties of CaCO3-CaP mixed cements
Even though the compressive strength of the CaCO3-CaP mixed cement remained poor in all
cases (£ 13 MPa), this would not be determinant for in vivo applications such as bone filling
especially  in  low  mechanical  stress  locations.  Moreover  these  properties  can  probably  be
improved by optimising the specific surface area of the reactive powders and thus the L/S
ratio.
The excellent cytocompatibility of the CaCO3-CaP mixed cement compositions revealed by
indirect  cytotoxicity  evaluation  is  probably  related  to  the  stability  of  pH  involved  in  the
setting  reaction  and  the  low  solubility  of  the  CaCO3  and  CaP  in  the  final  composition.
Another advantage of such CaCO3-CaP mixed cements is that their in vivo biodegradation
would release calcium, carbonate and phosphate ions and/or CO2 which are non-cytotoxic
metabolites as they are under the control of the organism.
A recent study on fresh anatomical pieces, showed that we can consider preparing CaCO3-
CaP mixed cements with the patient’s blood as liquid phase [40]. In addition, we can take
advantage  of  the  control  of  pH,  temperature  and  final  cement  composition  (resorption
properties) of CaCO3-CaP mixed cement by associating the paste with biologically  active
components (growth factors, specific proteins, platelets) promoting tissue repair, which could
be progressively released after implantation.
Conclusions
Several original CaCO3-CaP mixed cement compositions containing at least 40 % calcium
carbonate (w/w in the dry powder ingredients) have been proposed. The setting and hardening
reaction is essentially related to the formation of a poorly crystalline carbonated apatite and
the composition of the hardened cement can be biphasic (metastable crystalline CaCO3 phase
and poorly crystalline apatite). The possibility to control and adapt the composition of theNew CaCO3-CaP mixed cement compositions
final phase(s) and consequently the cement biodegradation properties is an interesting feature
of these cements.
We  did  not  detect  any  toxic  effects  on  human  osteoprogenitor  cells  suggesting  good
cytocompatibility of the CaCO3–CaP mixed cement compositions.
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Figure 1: X-ray diffraction diagrams of examples of calcium carbonate-calcium phosphate
mixed  cement  compositions  after  setting  and  hardening  compared  to  the  bone  X-ray
diffraction diagram. (V: vaterite, Ap: apatite, Br: brushite).
Figure 2: FTIR spectra of examples of calcium carbonate-calcium phosphate mixed cement
compositions after setting and hardening compared to the bone FTIR spectrum (V: vaterite,
Ar: aragonite).
Figure 3: Decomposition of the n2CO3 band (900-800 cm
-1) of (Ar+V+Br) cement  FTIR
spectrum (4 main subbands: type A (A), type B (B) and  non-apatitic (non-Ap) carbonate ions
in apatite and carbonate ions (Ar) in aragonite).
Figure 4: SEM micrographs of two types of CaCO3-CaP mixed cements:
a)  and b) (V+Br) cement
c)  and d) (V+TCPam) cement
Figure 5: Indirect cytotoxicity evaluation of two types of CaCO3-CaP mixed cement
compositions ((Ar+V+Br) and (Br+V)):
a)  Cell viability
b)  Metabolic activityNew CaCO3-CaP mixed cement compositions
 Table 1: Examples of calcium carbonate-calcium phosphate mixed cement compositions and
properties.
Powder
mixture
Powder ratio
(w:w)
L/S
(w/w)
Major final
phases
Setting
time
(min)
Compressive
strength
(MPa)
(V + Br) 1:1 0.50 PCA+V 60 13.0
(V + TCPam) 1:1 0.72 PCA+V 25 1.8
(Ar + V + Br) 1:2:4 0.71 PCA 30 7.4
   L = liquid; S = solid
   V = vaterite, Ar = aragonite
   Br = Brushite or dicalcium phosphate dihydrate (DCPD)
   TCPam: amorphous tricalcium phosphateNew CaCO3-CaP mixed cement compositions
Table 2: Carbonate content in CaCO3-CaP mixed cement final compositions.
Powder
mixture
Powder
weight ratio
Initial powder mixture
CO3
2- content (% w/w)
a
Final cement CO3
2- content
(% w/w)
b
V + Br 1:1
(L/S = 0.5)
30.0 % 17.5 %
V + TCPam 1:1
(L/S = 0.75)
30.0 % 21.2 %
Ar + V + Br 1:2:4
(L/S = 1)
26.7 % 10.0 %
L = liquid; S = solid
V = vaterite, Ar = aragonite
Br = Brushite or dicalcium phosphate dihydrate (DCPD)
TCPam: amorphous tricalcium phosphate
a Carbonate content calculated
b Carbonate content measured by coulometryNew CaCO3-CaP mixed cement compositions
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